@article{article, keywords = {morbidity management and disability prevention, MMDP, Morbidity management, Disability prevention, filarial lymphedema, Adherence}, author = {Ramar G and Sadhasivam A and Gnanasekaran V and Periyathambi M and Balakrishnan V and Kuttiatt V}, title = {Developing a scoring tool for assessing adherence to morbidity management and disability prevention (MMDP) practices in patients with filarial lymphedema: A pilot study.}, abstract = {
BACKGROUND:
Morbidity Management and Disability Prevention (MMDP) practices are essential in mitigating the progression of lymphedema and in preventing episodes of adenolymphangitis. Despite their importance, patients{\textquoteright} adherence to these prescribed practices has frequently been found to be suboptimal. Currently, there is a lack of a standardized tool for the objective assessment of patients{\textquoteright} adherence to MMDP practices in patients with filarial lymphedema. This study was undertaken to develop a scoring system for assessing patients{\textquoteright} adherence to MMDP and to validate this among patients attending a filariasis management clinic.
METHODOLOGY:
A scoring tool (VCRC MMDP Adherence Assessment Tool and VAAT score) was developed to evaluate adherence to MMDP practices across eight defined domains. The total score ranges from 0 to 40, reflecting the degree of adherence. This tool was validated through a cross-sectional study involving 90 patients diagnosed with varying grades of filarial lymphedema.
RESULTS:
Based on the VAAT score, patients were categorizable into three different levels of adherence: optimal adherence (>= 30), medium adherence (20-29) and poor adherence (\< 20). Among the 90 patients assessed, 21 (23\%) demonstrated optimal adherence, 47 (52\%) showed medium adherence and 22 (25\%) were categorized as having poor adherence.
CONCLUSION:
This study marks the first development and validation of a scoring system to assess adherence to MMDP practices in patients with filarial lymphedema. The tool proved useful in effectively identifying individuals with suboptimal adherence. However, further validation is required in a greater number of patients in a prospective manner and in different geographical and epidemiological settings.
}, year = {2026}, journal = {PloS one}, volume = {21}, pages = {1 - 8}, month = {09/2026}, issn = {1932-6203}, url = {https://pmc.ncbi.nlm.nih.gov/articles/PMC13626310/pdf/pone.0358191.pdf}, doi = {10.1371/journal.pone.0358191}, language = {ENG}, }